Homocysteine in Acute Coronary Syndrome

July 4, 2023 updated by: Mahmoud Abdelnasser Labib, Sohag University

Serum Homocysteine Level in the Setting of Acute Coronary Syndrome in Young Adult Patients

This study aims to determine the relation between high homocysteine levels and increased incidence of acute coronary syndrome in young patients

Study Overview

Status

Completed

Conditions

Acute Coronary Syndrome

Intervention / Treatment

Diagnostic test: Homocysteine level

Detailed Description

Cross sectional study to:

assess homocysteine level in young adult patients presenting with acute coronary syndrome

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Egypt
- - Sohag, Egypt
    - Sohag University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

All patients presented with acute coronary syndrome admitted to coronary care unit of Sohag University hospital according to inclusion and exclusion criteria

Description

Inclusion Criteria:

- The patients who presented in the hospital with chest pain consistent with acute coronary syndrome with any of the following features:
1. Electrocardiogram (ECG) changes:
  - ST elevation
  - ST depression
  - T wave inversion
  - recent left bundle branch block
2. Troponin T elevation (Norma value < 0.06)
  2- Age: -Between 18- 40 years (Group A) - Age > 40 years (Group B)
  Exclusion Criteria:
  1. Chest pain not consistent with acute coronary syndrome
  2. Chronic kidney disease (CKD)
  3. Rheumatic heart disease (RHD)
  4. Congenital heart disease
  5. Anemia
  6. Cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Coronary care unit admission with acute coronary syndrome Time Frame: From date of randomization up to 1 month	Acute coronary syndrome hospitalization and cardiovascular deathes and estimated hazard ratios (HR) by use of multivariable Cox regression models	From date of randomization up to 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

Study Chair: Mohammed E Amin, Lecturer, Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Liu J, Quan J, Li Y, Wu Y, Yang L. Blood homocysteine levels could predict major adverse cardiac events in patients with acute coronary syndrome: A STROBE-compliant observational study. Medicine (Baltimore). 2018 Oct;97(40):e12626. doi: 10.1097/MD.0000000000012626.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 30, 2021

Primary Completion (Actual)

May 30, 2023

Study Completion (Actual)

July 1, 2023

Study Registration Dates

First Submitted

November 6, 2021

First Submitted That Met QC Criteria